Background: Overexpression of aspartate β-hydroxylase (ASPH) in human tumors contributes to their progression by stimulating cell proliferation, migration, and invasion. Several signaling pathways affected by ASPH have been identified, but the high number of potential targets of ASPH hydroxylation suggests that additional mechanisms may be involved. This study was performed to reveal new targets of ASPH signaling. Methods: The effect of ASPH on the oncogenicity of three mouse tumor cell lines was tested using proliferation assays, transwell assays, and spheroid invasion assays after inhibition of ASPH with the small molecule inhibitor MO-I-1151. ASPH was also deactivated with the CRISPR/Cas9 system. A transcriptomic analysis was then performed with bulk RNA sequencing and differential gene expression was evaluated. Expression data were verified by quantitative PCR and immunoblotting. Results: Inhibition or abrogation of ASPH reduced proliferation of the cell lines and their migration and invasiveness. Among the genes with differential expression in more than one cell line, two members of the lymphocyte antigen 6 (Ly6) family, Ly6a and Ly6c1, were found. Their downregulation was confirmed at the protein level by immunoblotting, which also showed their reduction after ASPH inhibition in other mouse cell lines. Reduced production of the Ly6D and Ly6K proteins was shown after ASPH inhibition in human tumor cell lines. Conclusions: Since increased expression of Ly6 genes is associated with the development and progression of both mouse and human tumors, these results suggest a novel mechanism of ASPH oncogenicity and support the utility of ASPH as a target for cancer therapy.

Department of Genetics and Microbiology Faculty of Science Charles University BIOCEV Vestec Czech Republic

Department of Pharmaceutical Sciences College of Pharmacy Glendale Midwestern University Glendale AZ USA

Zobrazit více v PubMed

Fu D, Hu Z, Xu X, Dai X, Liu Z. Key signal transduction pathways and crosstalk in cancer: Biological and therapeutic opportunities. Transl Oncol. 2022;26:101510. PubMed PMC

Yip HYK, Papa A. Signaling pathways in cancer: therapeutic targets, combinatorial treatments, and new developments. Cells. 2021;10:659. PubMed PMC

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: A brief review. Adv Pharm Bull. 2017;7:339–48. PubMed PMC

Aihara A, Huang C-K, Olsen MJ. et al. A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma. Hepatology. 2014;60:1302–13. PubMed PMC

Dong X, Lin Q, Aihara A. et al. Aspartate β-hydroxylase expression promotes a malignant pancreatic cellular phenotype. Oncotarget. 2014;6:1231–48. PubMed PMC

Iwagami Y, Huang C-K, Olsen MJ. et al. Aspartate β-hydroxylase modulates cellular senescence through glycogen synthase kinase 3β in hepatocellular carcinoma. Hepatology. 2016;63:1213–26. PubMed PMC

Sturla L-M, Tong M, Hebda N. et al. Aspartate-β-hydroxylase (ASPH): a potential therapeutic target in human malignant gliomas. Heliyon. 2016;2:e00203. PubMed PMC

Ogawa K, Lin Q, Li L. et al. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway. J Hematol Oncol. 2019;12:144. PubMed PMC

Lavaissiere L, Jia S, Nishiyama M. et al. Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest. 1996;98:1313–23. PubMed PMC

Cantarini MC, Monte SM de la, Pang M. et al. Aspartyl-asparagyl β hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology. 2006;44:446–57. PubMed

Wands JR, Kim M. WNT/β-catenin signaling and hepatocellular carcinoma. Hepatology. 2014;60:452. PubMed

Huyan T, Li Q, Dong D-D, Yang H, Xue X-P, Huang Q-S. Development of a novel anti-human aspartyl-(asparaginyl) β-hydroxylase monoclonal antibody with diagnostic and therapeutic potential. Oncol Lett. 2017;13:1539. PubMed PMC

Nordquist LT, Shore ND, Elist JJ. et al. Phase 1 open-label trial to evaluate the safety and immunogenicity of PAN-301-1, a novel nanoparticle therapeutic vaccine, in patients with biochemically relapsed prostate cancer. J Clin Oncol. 2018;36:e15166–e15166.

Kanwal M, Smahel M, Olsen M, Smahelova J, Tachezy R. Aspartate β-hydroxylase as a target for cancer therapy. J Exp Clin Cancer Res. 2020;39:163. PubMed PMC

Tomimaru Y, Mishra S, Safran H. et al. Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma. Vaccine. 2015;33:1256–66. PubMed PMC

Ince N, de la Monte SM, Wands JR. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res. 2000;60:1261–6. PubMed

Stenflo J, Holme E, Lindstedt S. et al. Hydroxylation of aspartic acid in domains homologous to the epidermal growth factor precursor is catalyzed by a 2-oxoglutarate-dependent dioxygenase. Proc Natl Acad Sci USA. 1989;86:444–7. PubMed PMC

Luu M, Sabo E, de la Monte SM. et al. Prognostic value of aspartyl (asparaginyl)-β-hydroxylase/humbug expression in non-small cell lung carcinoma. Hum Pathol. 2009;40:639–44. PubMed PMC

Huang C-K, Iwagami Y, Aihara A. et al. Anti-tumor effects of second generation β-hydroxylase inhibitors on cholangiocarcinoma development and progression. PLOS ONE. 2016;11:e0150336. PubMed PMC

Peng H, Guo Q, Xiao Y. et al. ASPH regulates osteogenic differentiation and cellular senescence of BMSCs. Front Cell Dev Biol. 2020;8:872. PubMed PMC

Yao W-F, Liu J-W, Huang D-S. MiR-200a inhibits cell proliferation and EMT by down-regulating the ASPH expression levels and affecting ERK and PI3K/Akt pathways in human hepatoma cells. Am J Transl Res. 2018;10:1117. PubMed PMC

Zou Q, Hou Y, Wang H. et al. Hydroxylase activity of ASPH promotes hepatocellular carcinoma metastasis through epithelial-to-mesenchymal transition pathway. EBioMedicine. 2018;31:287–98. PubMed PMC

Zheng G, Cox T, Tribbey L. et al. Synthesis of a FTO inhibitor with anticonvulsant activity. ACS Chem Neurosci. 2014;5:658–65. PubMed PMC

Brewitz L, Tumber A, Thalhammer A, Salah E, Christensen KE, Schofield CJ. Synthesis of novel pyridine-carboxylates as small-molecule inhibitors of human aspartate/asparagine-β-hydroxylase. ChemMedChem. 2020;15:1139–49. PubMed PMC

Nagaoka K, Bai X, Ogawa K. et al. Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma. Cancer Lett. 2019;449:87–98. PubMed PMC

Lin K-Y, Guarnieri FG, Staveley-O'Carroll KF. et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56:21–6. PubMed

Smahel M, Sima P, Ludvıikova V, Marinov I, Pokorna D, Vonka V. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine. 2003;21:1125–36. PubMed

Smahel M, Smahelova J, Tejklova P, Tachezy R, Jelinek F. Analysis of tumor progression by transcriptional profiling of mouse MK16 cell lines transformed with human papillomavirus type 16 E6 and E7 oncogenes and activated H-ras. Oncol Rep. 2005;14:1665–74. PubMed

Ljunggren HG, Kärre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med. 1985;162:1745–59. PubMed PMC

Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 1975;35:218–24. PubMed

Lelekakis M, Moseley JM, Martin TJ. et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 1999;17:163–70. PubMed

Hatina J, Hajkova L, Peychl J. et al. Establishment and characterization of clonal cell lines derived from a fibrosarcoma of the H2-K/V-JUN transgenic mouse. A model of H2-K/V-JUN mediated tumorigenesis. Tumour Biol. 2003;24:176–84. PubMed

Piatakova A, Polakova I, Smahelova J, Johari SD, Nunvar J, Smahel M. Distinct responsiveness of tumor-associated macrophages to immunotherapy of tumors with different mechanisms of major histocompatibility complex class I downregulation. Cancers. 2021;13:3057. PubMed PMC

Mootha VK, Lindgren CM, Eriksson K-F. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267–73. PubMed

Subramanian A, Tamayo P, Mootha VK. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50. PubMed PMC

Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27:1739–40. PubMed PMC

Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417–25. PubMed PMC

Palomero T, Lim WK, Odom DT. et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A. 2006;103:18261–6. PubMed PMC

Dinchuk JE, Henderson NL, Burn TC. et al. Aspartyl β-hydroxylase (Asph) and an evolutionarily conserved isoform of Asph missing the catalytic domain share exons with junctin. J Biol Chem. 2000;275:39543–54. PubMed

Setiadi AF, David MD, Seipp RP, Hartikainen JA, Gopaul R, Jefferies WA. Epigenetic control of the immune escape mechanisms in malignant carcinomas. Mol Cell Biol. 2007;27:7886–94. PubMed PMC

Manning J, Indrova M, Lubyova B. et al. Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours. Immunology. 2008;123:218–27. PubMed PMC

Lin Q, Chen X, Meng F. et al. Asph-notch axis guided exosomal delivery of prometastatic secretome renders breast cancer multi-organ metastasis. Mol Cancer. 2019;18:156. PubMed PMC

Gan X, Li S, Wang Y. et al. Aspartate β-hydroxylase serves as a prognostic biomarker for neoadjuvant chemotherapy in gastric cancer. Int J Mol Sci. 2023;24:5482. PubMed PMC

Huang C-K, Iwagami Y, Zou J. et al. Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation. Cancer Lett. 2018;429:1–10. PubMed PMC

Benelli R, Costa D, Mastracci L. et al. Aspartate-β-hydroxylase: a promising target to limit the local invasiveness of colorectal cancer. Cancers. 2020;12:971. PubMed PMC

Liu D, Xu C, Liu Y. et al. A systematic survey of LU domain-containing proteins reveals a novel human gene, LY6A, which encodes the candidate ortholog of mouse Ly-6A/Sca-1 and is aberrantly expressed in pituitary tumors. Front Med. 2023;17:458–75. PubMed

Park JW, Park JM, Park DM, Kim D-Y, Kim HK. Stem cells antigen-1 enriches for a cancer stem cell-like subpopulation in mouse gastric cancer. Stem Cells. 2016;34:1177–87. PubMed

Remsik J, Pickova M, Vacek O. et al. TGF-β regulates Sca-1 expression and plasticity of pre-neoplastic mammary epithelial stem cells. Sci Rep. 2020;10:11396. PubMed PMC

Upadhyay G, Yin Y, Yuan H, Li X, Derynck R, Glazer RI. Stem cell antigen-1 enhances tumorigenicity by disruption of growth differentiation factor-10 (GDF10)-dependent TGF-β signaling. Proc Natl Acad Sci U S A. 2011;108:7820–5. PubMed PMC

AlHossiny M, Luo L, Frazier WR. et al. Ly6E/K signaling to TGFβ promotes breast cancer progression, immune escape, and drug resistance. Cancer Res. 2016;76:3376–86. PubMed PMC

Loughner CL, Bruford EA, McAndrews MS, Delp EE, Swamynathan S, Swamynathan SK. Organization, evolution and functions of the human and mouse Ly6/uPAR family genes. Hum Genomics. 2016;10:10. PubMed PMC

Luo L, McGarvey P, Madhavan S, Kumar R, Gusev Y, Upadhyay G. Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome. Oncotarget. 2016;7:11165–93. PubMed PMC

Upadhyay G. Emerging role of lymphocyte antigen-6 family of genes in cancer and immune cells. Front Immunol. 2019;10:819. PubMed PMC

Park S, Park D, Han S. et al. LY6K depletion modulates TGF-β and EGF signaling. Cancer Med. 2023;12:12593–607. PubMed PMC

Guo D, Liu Y, Jiang Y. et al. A narrative review of the emerging role of lymphocyte antigen 6 complex locus K in cancer: from basic research to clinical practice. Ann Transl Med. 2022;10:26. PubMed PMC

Brewitz L, Onisko BC, Schofield CJ. Combined proteomic and biochemical analyses redefine the consensus sequence requirement for epidermal growth factor-like domain hydroxylation. J Biol Chem. 2022;298:102129. PubMed PMC

Holt LJ, Siddle K. Grb10 and Grb14: enigmatic regulators of insulin action - and more? Biochem J. 2005;388:393–406. PubMed PMC

Morzyglod L, Caüzac M, Popineau L. et al. Growth factor receptor binding protein 14 inhibition triggers insulin-induced mouse hepatocyte proliferation and is associated with hepatocellular carcinoma. Hepatology. 2017;65:1352–68. PubMed

Huang O, Jiang M, Zhang X. et al. Grb14 as an independent good prognosis factor for breast cancer patients treated with neoadjuvant chemotherapy. Jpn J Clin Oncol. 2013;43:1064–72. PubMed

Yang P, Wei J, Li W. et al. High expression of growth factor receptor-bound protein 14 predicts poor prognosis for colorectal cancer patients. Biotechnol Lett. 2016;38:1043–7. PubMed

Gómez-Herranz M, Taylor J, Sloan RD. IFITM proteins: Understanding their diverse roles in viral infection, cancer, and immunity. J Biol Chem. 2023;299:102741. PubMed PMC

Chan T-C, Wu W-J, Li W-M, Shiao M-S, Shiue Y-L, Li C-F. SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma. Theranostics. 2020;10:11775–93. PubMed PMC

Ye B, Ding K, Li K, Zhu Q. Study on the role of SLC14A1 gene in biochemical recurrence of prostate cancer. Sci Rep. 2022;12:17064. PubMed PMC

Zhou Y, Yuan Y, Zhang Q, Shen Y, Chen W, Yan L. Downregulation of SLC14A1expression indicates poor prognosis and promotes the progression of non-small cell lung cancer. Ann Clin Lab Sci. 2022;52:753–62. PubMed

Kikuchi A, Matsumoto S, Sada R. Dickkopf signaling, beyond Wnt-mediated biology. Semin Cell Dev Biol. 2022;125:55–65. PubMed

Loboda A, Jozkowicz A, Dulak J. HO-1/CO system in tumor growth, angiogenesis and metabolism — Targeting HO-1 as an anti-tumor therapy. Vascul Pharmacol. 2015;74:11–22. PubMed

Shi H, Hou B, Li H, Zhou H, Du B. Cyclophosphamide induces the ferroptosis of tumor cells through heme oxygenase-1. Front Pharmacol. 2022;13:839464. PubMed PMC

Heterogeneous Response of Tumor Cell Lines to Inhibition of Aspartate β-hydroxylase